BREAST CANCER PREVENTION: LIFESTYLE CHANGES AND CHEMOPREVENTION

REFERENCES

• Jemal A, Siegel R, Xu J et al. Cancer statistics 2010. CA Cancer J Clin 2010; 60: 277–300.
   PubMed Web of Science ®Google Scholar
• Kellen E, Vansant G, Christiaens MR et al. Lifestyle changes and breast cancer prognosis: a review. Breast Cancer Res Treat 2009; 114: 13–22.
   PubMed Web of Science ®Google Scholar
• Nyström L, Andersson I, Bjurstam N. et al. Long-term effects of mammographic screening: updated overview of the Swedish randomized trials. Lancet 2002; 359: 909–919.
   PubMed Web of Science ®Google Scholar
• Elmore JG, Armstrong K, Lehman CD et al. Screening for breast cancer. JAMA 2005; 293: 1245–1256.
   PubMed Web of Science ®Google Scholar
• Bijwaard H, Brenner A, Dekkers F et al. Breast cancer risk from different mam-mography screening practices. Radiat Res 2010; 174(3): 367–376.
   Web of Science ®Google Scholar
• Kriege M, Brekelmans C, Boetes C et al. Efficacy of MRI and mammography for Breast-Cancer screening in women with a familial or genetic predisposition. New Engl J med 2004; 351: 427–437.
   PubMed Web of Science ®Google Scholar
• Wertheimer MD, Costanza ME, Dodson TF, D'Orsi C, Pastides H, Zapka JG. Increasing the effort toward breast cancer detection. JAMA 1986; 225: 1311–1315.
   Google Scholar
• Kaplan CP, Haas JS, Pérez-stable EJ. Breast cancer risk reduction options: aware-ness, discussion and use. Cancer Epidemiol Biomarkers Prey 2006; 15: 162–166.
   PubMed Web of Science ®Google Scholar
• Boffetta P, Tubiana M, Hill C et al. The causes of cancer in France. Ann Oncol 2009; 20(3): 550–555.
   Web of Science ®Google Scholar
• Mahoney MC, Bevers T, Linos E et al. Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin 2008; 58: 347–371.
   Web of Science ®Google Scholar
• Colditz GA, Rosner BA, Chen WY. Risk factors for breast cancer according to estro-gen and progesterone receptor status. J Natl Cancer Inst 2004; 96(3): 218–228.
   Web of Science ®Google Scholar
• Singletary SE. Rating the risk factors for breast cancer. Ann Surg 2003; 237: 474–484.
   PubMed Web of Science ®Google Scholar
• Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 2007; 96(1): 11–15.
   PubMed Web of Science ®Google Scholar
• Brinton LA, Hoover R, Fraumeni JF Jr. Epidemiology of minimal breast cancer. JAMA 1983; 249:483–487.
   Web of Science ®Google Scholar
• Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002; 360: 187–195.
   PubMed Web of Science ®Google Scholar
• Cottet V, Touvier M, Fournier A et al. Postmenopausal breast cancer risk and dietary patterns in the E3N-EPIC prospective cohort study. Am J Epidemiol 2009; 170(10): 1257–1267.
   PubMed Web of Science ®Google Scholar
• Monninkhof EM, Elias SG, Vlems FA, et al. Physical activity and breast cancer: a systematic review. Epidemiology 2007; 18: 137–157.
   PubMed Web of Science ®Google Scholar
• Ursin G, Ma H, Wu AH, et al Mammographic density and breast cancer in three ethnic groups Cancer Epidemiol Biomarkers Prey 2003; 12: 332–338.
   PubMed Web of Science ®Google Scholar
• King MC, Marks JH, Mandell JB Breast and ovarian cancer risks due to inherited mutations in BRCA 1 and BRCA2. Science 2003; 302: 643–646.
   PubMed Web of Science ®Google Scholar
• Pijpe A, Manders P, Brohet RM Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers. Breast cancer Res Treat 2010; 120(1): 235–244.
   Web of Science ®Google Scholar
• Asselin-Labat ML, Vaillant F, Sheridan JM Control of mammary stem cell func-tion. Nature 2010; 465: 798–802.
   PubMed Web of Science ®Google Scholar
• Joshi PA, Jackson HW, Beristain AG et al Progesterone induces adult mammary stem cell expansion. Nature 2010; 465, 803–807.
   PubMed Web of Science ®Google Scholar
• Hemminki K, Försti A, Sundquist J et al Preventable breast cancer is postmen-opausal. Breast Cancer Res Treat 2010; May 8 Epub.
   Google Scholar
• Claus EB, Risch N, Thompson WD Genetic analysis of breast cancer in the can-cer and steroid hormone study. Am J Hum Genet 1991; 48: 232–242.
   PubMed Web of Science ®Google Scholar
• Gail MH, Brinton LA, Byer DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Nat Cancer Inst 1989; 81:1879–1886.
   PubMed Web of Science ®Google Scholar
• Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst 2007; 99: 1782–1792.
   PubMed Web of Science ®Google Scholar
• Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998; 62: 145–158.
   PubMed Web of Science ®Google Scholar
• Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat med 2004; 23(7): 111–130.
   Web of Science ®Google Scholar
• Evans DG, Howell A. Breast cancer risk-assessment models. Breast Cancer Res 2001; 61: 5683–5687.
   Google Scholar
• Barlow WE, White E, Ballard-Barbash R et al. Prospective breast cancer risk pre-dicition model for women undergoing screening mammography./Naff Cancer Inst. 2006; 98(17): 1204–1214.
   Google Scholar
• Tice JA, Cummings SR, Smith-Bindman R et al. Using clinical factors and mam-mographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008; 148(5): 337–347.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Tice JA, Bauer S et al. Prevention of breast cancer in postmeno-pausal women: approaches to estimating and reducing risk. J Natl Cancer Inst 2009; 101: 384–398.
   PubMed Web of Science ®Google Scholar
• Meijers-Heijboer H, Van denouweland A, Klijn J Low-penetrance susceptibility to breast cancer due to CHEK2()1100deIC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31: 55–59.
   PubMed Web of Science ®Google Scholar
• Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study iden-tifies novel breast cancer susceptibility gene. Nat Genet 2007; 39: 165–167.
   Web of Science ®Google Scholar
• Pharoah PD, Antoniou AC, Easton DF et al Polygenes, risk prediction, and tar-geted prevention of breast cancer. N Engl J Med 2008; 358: 2796–2803.
   PubMed Web of Science ®Google Scholar
• Ewertz M, Duffy SW, Ada mi HO et al. Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. Int J Cancer 1990; 46: 597–603.
   PubMed Web of Science ®Google Scholar
• Chie WC, Hsieh C, Newcomb PA et al. Age at any full-term pregnancy and breast cancer risk. Am J Epidemiol 2000; 51: 715–722.
   Google Scholar
• Russo J, Hu YF, Silva IDCG et al. Cancer risk related to mammary gland structure and development. J Electron Microsc Tech 1992; 52: 204–223.
   Google Scholar
• Russo J, Mailo D, Hu YF et al. Breast differentiation and its implication in cancer prevention. Clin Cancer Res 2005; 11: 931–936.
   PubMed Web of Science ®Google Scholar
• Russo J, Moral R, Balogh GA et al. The protective role of pregnancy in breast cancer. Breast cancer Res 2005; 7: 131–142.
   PubMed Web of Science ®Google Scholar
• Lambe M, Hsieh C, Trichopouls D et al Transient increase in the risk of breast-cancer after giving birth. NEJM 1994; 331: 5–9.
   PubMed Web of Science ®Google Scholar
• Albrektsen G, Heuch I, Thoresen S et al. Clinical stage of breast cancer by par-ity, age at birth, and time since birth: a progressive effect of pregnancy hor-mones? Cancer epidemiol biomarkers prey 2006; 15: 65–69.
   PubMed Web of Science ®Google Scholar
• Daling JR, Malone KE, Doody DR et al. The relation of reproductive factors to mortality from breast cancer. Cancer epidemiol biomarkers prey 2002; 11: 235.
   PubMed Web of Science ®Google Scholar
• Polyak K. Pregnancy and breast cancer: the other side of the coin. Cancer cell 2006; 151–153.
   Web of Science ®Google Scholar
• Bemis LT, Schedin P. Reproductive state of rat mammary gland stroma modu-lates human breast cancer cell migration and invasion. Cancer Res 2000; 60: 3414–3418.
   PubMed Web of Science ®Google Scholar
• Ursin G, Bernstein L, Lord SJ et al. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. Br J Cancer 2005; 93: 364–371.
   PubMed Web of Science ®Google Scholar
• Ma H, Wang Y, Sullivan-Halley J et al. Use of Four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res 2010; 70(2): 575–587.
   Web of Science ®Google Scholar
• Collaborative group on hormonal factors in breast cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemio-logical studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. The lancet 2002; 360: 187–195.
   PubMed Web of Science ®Google Scholar
• Jernström H, Lubinsiki J, Lynch T et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carries. J Natl Cancer Inst 2004; 96: 1094–1098.
   PubMed Web of Science ®Google Scholar
• Russo J, Russol H Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomarkers Prey 1994; 3: 353–364.
   PubMed Web of Science ®Google Scholar
• Petrakis NL, Wrensch MR, Ernster VL et al. Influence of pregnancy and lactation on serum and breast fluid estrogen levels: implications for breast cancer risk. Int J Cancer 1987; 40: 587–591.
   PubMed Web of Science ®Google Scholar
• Tworoger SS, Hankinson SE. Prolactin and breast cancer risk. Cancer Lett 2006; 243: 160–169.
   PubMed Web of Science ®Google Scholar
• Bercovich D, Goodman G. Pregnancy and lactation after breast cancer elevate plasma prolactin, do not shorten and may prolong survival. Med Hypotheses 2009; 73: 942–947.
   PubMed Web of Science ®Google Scholar
• Nevalainen MT, Jianwu Xie, Torhorst J et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 2004; 22: 2053–2060.
   PubMed Web of Science ®Google Scholar
• Collaborative group on hormonal factors in breast cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347(9017): 1713–1727.
   PubMed Web of Science ®Google Scholar
• Marchbanks PA, McDonald JA, Hoyt G et al. Oral contraceptives and the risk of breast cancer. New Eng J Med 2002; 346: 2025–2032.
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Colditz GA, Hankinson SE. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer epidemiol biomarkers prey 2010 19(10): 2496–2502.
   PubMed Web of Science ®Google Scholar
• Prentice RL, Caan B, Chlebowski RT et al. Low-fat dietary pattern and risk of invasive breast cancer: the women's health initiative randomized controlled dietary modification trial. JAMA 2006; 295: 629–642.
   PubMed Web of Science ®Google Scholar
• Wu A, Pike M, Stramm D. Meta-analysis: dietary fat intake, serum estrogen lev-els and risk of breast cancer. J Natl Cancer lnst 1999; 91: 529–534.
   PubMed Web of Science ®Google Scholar
• Boyd NF, Greenberg C, Lockwoord G et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a ran-domized trial. J Natl Cancer lnst 1997; 89: 488–496.
   PubMed Web of Science ®Google Scholar
• Lew JQ Freedman ND, Leitzmann MF et al. Alcohol and risk of breast can-cer by histologic type and hormone receptor status in postmenopausal women: the NIH-AARP Diet and Health Study. Am J epidemiol 2009; 170(3): 308–317.
   Web of Science ®Google Scholar
• Key J, Hodgson S. Omar RZ et al. Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. Cancer causes control 2006; 17(6): 759–770.
   Web of Science ®Google Scholar
• Benzon LS, Vogel U, Christensen J et al. Interaction between ADH1C Arg(272)Gln and alcohol intake in relation to breast cancer risk suggests that ethanol is the causal factor in alcohol related breast cancer. Cancer Lett 2010; 295: 191–197.
   Web of Science ®Google Scholar
• Friedenreich CM, Cust AE Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects. Br J Sports Med 2008; 42: 36–647.
   Web of Science ®Google Scholar
• Peters TM, Schatzkin A, Gierach GL et al Physical activity and postmenopausal breast cancer risk in the NIH-AARP diet and health study Cancer epidemiol bio-markers prey 2009; 18(1).
   Web of Science ®Google Scholar
• Friedenreich CM, Woolcott CG, Tiernan A et al Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise interven-tion among postmenopausal women. J Clin Oncol 2010; 28(9): 1458–1466.
   Web of Science ®Google Scholar
• Neilson HK, Friedenreich CM, Brockton NT, Millikan RC. Physical activity and postmenopausal breast cancer: proposed biologic mechanisms and areas for future research. Cancer Epidemiol Biomarkers Prey 2009; 18(1): 11–27.
   Web of Science ®Google Scholar
• The endogenous hormones and breast cancer collaborative Group. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet 2010; 11:530–542.
   Web of Science ®Google Scholar
• Kabat GC, Kim M, Caan BJ et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int.' Cancer 2009; 125(11): 2704–2710.
   Web of Science ®Google Scholar
• Goodwin PJ. Insulin in the adjuvant breast cancer setting: a novel therapeutic tar-get for lifestyle and pharmacologic interventions?JClin Oncol 2008;26(6):833–834.
   Google Scholar
• Jiralerspong S, Palla SL, Giordano SH et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast can-cer. J Clin Oncol 2009; 27: 3297–3302.
   PubMed Web of Science ®Google Scholar
• Goodwin P. Metformin in breast cancer: time for action. J Clin Oncol 2009; 27: 3271–3273.
   PubMed Web of Science ®Google Scholar
• World Health Organization - international agency for research on cancer (IARC): IARC monographs on the evaluation of carcinogenic risks to humans - Voume 83: tobacco smoke and involuntary smoking - summary of data reported and evaluation.
   Google Scholar
• Reynolds P. Hurley S, Debbie E. Active smoking, household passive smoking and breast cancer: evidence from the California Teachers study. J N Cancer lnst 2004; 96(1): 29–37.
   Web of Science ®Google Scholar
• Li Cl, Daling JR, Porter Pl. Relationship between potentially modifiable lifestyle factors and risk of second primary contra lateral breast cancer amongst women diagnosed with estrogen receptor positive invasive breast cancer. J Clin Oncol 2009; 27(32): 5312–5318.
   Web of Science ®Google Scholar
• Barett-Connor E Hormone replacement therapy. BMJ 1998; 317:457–461.
   Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 05–613.
   Web of Science ®Google Scholar
• Lee S, Ross RK, Pike MC. An overview of menopausal oestrogen-progestin hor-mone therapy and breast cancer risk. Br J Cancer 2005; 92: 2049–2058.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus proges-tin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. JAMA 2003; 289: 3243–3253.
   PubMed Web of Science ®Google Scholar
• Beral V, Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427.
   PubMed Web of Science ®Google Scholar
• Prentice RL, Chlebowski RT, Stefanick ML, et al Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008; 17:1207–121.
   Web of Science ®Google Scholar
• Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and obser-vational study. Am J Epidemiol 2008; 167: 1407–1415.
   PubMed Web of Science ®Google Scholar
• Fournier A, Mesrine S, Boutron-Ruault MC et al. Estrogen-progestagen meno-pausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risk? J Clin Oncol 2009; 27(31): 5138–5143.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associ-ated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107(1): 103–111.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Breast cancer Res Treat 2008; (107): 103–111.
   PubMed Web of Science ®Google Scholar
• Cummings S, Ettinger B, Delmas P et al. The effects of tibolone in older post-menopausal women. NEJM 2008; 359(7): 697–708.
   PubMed Web of Science ®Google Scholar
• Clarke CA, Glaser SL, Uratsu SL, et al. Recent declines in hormone therapy uti-lization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006; 24: 49–50.
   PubMed Web of Science ®Google Scholar
• Bernstein L. Combined hormone therapy at menopause and breast cancer: a warning - short term use increases risk. J Clin Oncol 2009; 27(31): 5116–5119.
   Web of Science ®Google Scholar
• Hunter DJ, Kraft P. Jacobs KB et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast can-cer. Nat Genet 2007; 39: 870–874.
   PubMed Web of Science ®Google Scholar
• Prentice RL, Huang Y, Hind DA. Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer epidemiol biomarkers prey 2009; 18: 3079–3085.
   PubMed Web of Science ®Google Scholar
• Fackenthal JD, Olopade H. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7: 937–948.
   Web of Science ®Google Scholar
• Easton DF, Hopper JL, Thomas DC et al. Breast cancer risks for BRCA1/2 carriers. Science 2004; 306: 2187–2191.
   Web of Science ®Google Scholar
• Moorman PG, Iversen ES, Marcom PK et al. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA 2: a multi-center case-only analysis. Breast Cancer Res Treat 2010 Mar 23 Epub.
   Web of Science ®Google Scholar
• Narod SA, Dubé MP, Klijn J et al. Oral contraceptives and the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers. J Natl Cancer Inst 2002; 94(23): 1773–1779.
   Web of Science ®Google Scholar
• Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mecha-nisms of action and application to clinical practice. N Engl J Med 2003; 348(12): 1192.
   Google Scholar
• Veronesi U, Maisonneuve P. Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hys-terectomised women. Lancet 1998; 352: 93–97.
   PubMed Web of Science ®Google Scholar
• Powles T, Eeles R, Ashly S et al. Interim analysis of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998; 352: 98–101.
   PubMed Web of Science ®Google Scholar
• Fisher B, Constantino JP, Wickerham DL Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel project P-1 study. J Nat Cancer Inst 2005; 97(22): 1652–1662.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Forbesf JF, Sestak I et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96 months follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007; 99(4): 272–282.
   Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282: 637–645.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in post-menopausal women: results from the MORE rand-omized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281: 2189–2197.
   PubMed Web of Science ®Google Scholar
• Martino S, Cauley JA, Barrett-Connor E et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751–1761.
   PubMed Web of Science ®Google Scholar
• Vogel V. Effects of tamoxifen vs Raloxifen on the risk of developing invasive breast cancer and other disease outcomes. JAMA 2006; 295: 2727–2741.
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. Cancer Prey Res 2010; 3(6): 696–706.
   PubMed Web of Science ®Google Scholar
• McClung MR, Skis E, Cummings SR et al. Prevention of bone loss in postmeno-pausal women treated with lasofoxifene compared with raloxifene. Menopause 2006; 13: 377–386.
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ensrud K, Delmas PD et al Lasofoxifene in postmenopausal women with osteoporosis. N Eng J Med 2010; 362(8): 686–696.
   PubMed Web of Science ®Google Scholar
• Cummings SR, McClung M, Reginster JY et al. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res 2010 Epub ahead of print.
   Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Guglielmini P et al. Switiching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006; 17.
   Google Scholar
• Coates AS, Keshaviah A, Thürlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486–492.
   PubMed Web of Science ®Google Scholar
• Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007; 369: 559–570.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S et al A randomized trial of letrozole in postmeno-pausal women after five years of tamoxifen therapy for early-stage breast can-cer. N Engl J Med 2003; 349: 1793–1802.
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 2005; 365: 60–62.
   PubMed Web of Science ®Google Scholar
• Cuzick J Aromatase inhibitors for breast cancer prevention? J Clin Oncol 2005; 23: 1636–1643.
   PubMed Web of Science ®Google Scholar
• Goss PE, Strasser-Weippl K. Prevention strategies with aromatase inhibitors. Clin Cancer Res 2004; 10: 3725–3795.
   Web of Science ®Google Scholar
• Goss PE, James NI, Ales-Martinez JE et al. Exemestane for breast cancer pre-vention in postmenopausal women. N Eng J Med 2011; 364 (25): 2381–2391.
   PubMed Web of Science ®Google Scholar
• Chlebowski R, Chen Z, Cauley J et al. Oral bisphosphonates use and breast can-cer incidence in postmenopausal women. J Clin Oncol 2010 Epub Jun 21.
   Google Scholar
• Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopuasal breast cancer. N Engl J Med 2009; 360: 679–691.
   PubMed Web of Science ®Google Scholar
• Eidtmann H, Bundred NJ, DeBoer R et al: The effect of zoledronic acid on aro-matase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving ajuvant letrozole: 36 months follow-up of ZO-FAST. 31't annual Meeting of the San Antonio Breast Cancer Symposium, December 10–14, 2008, San Antonia, TX ( abstr 44).
   Google Scholar
• Bedard PL, Body J, Piccart-Gebhart MJ: Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjucant bisphosphonate story in early breast cancer. J Clin Oncol 2009; 27: 4043–4046.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Morishige K, Sawada K et al. Aledronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem Biophys Res Commun 2007; 354: 478–484.
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Galluzzo S et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007; 13: 4482–4486.
   PubMed Web of Science ®Google Scholar
• Caccamo N, Meraviglia S, Scarpa F et al. Aminobisphosphonate-activated gamma delta T cells in immunotherapy of cancer: doubts no more. Expert opin Biol Ther 2008; 8: 875–883.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Y, Hill J et al The rexinoid bexarotene prevents the development of premalignant lesions in MMTV-erb2 mice. Br J Cancer 2008; 98(8): 1380–1388.
   Web of Science ®Google Scholar
• Cook NR, Lee IM, Gaziano JM. Low-dose aspirin in the primary prevention of cancer The Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 47–55.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Filioussi K, Tsavaris N et al. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005; 23(34): 8606–8612.
   PubMed Web of Science ®Google Scholar
• Crew KD, Gammon MD, Steck SE et al. Association between plasma 25-hydro-cyvitamin D and breast cancer risk. Cancer Prey Res 2009; 6:598–604.
   Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 245–251.
   Web of Science ®Google Scholar